Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies. The companies noted that this definitive agreement will include Adverum’s lead candidate, Ixo-vec. Adverum and Lilly’s merger…
Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma | Ophthalmology Times
Image credit: AdobeStock/Christoph Burgstedt Positive results from the ongoing Phase 2 OptimUM-09 trial are encouraging for the treatment of uveal melanoma (UM). According to the press release from IDEAYA Biosciences, the developers of this therapeutic candidate, “there are currently no…
Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times
(Image Credit: AdobeStock) The structural differences among newer second-generation anti-VEGF agents—and their implications for clinical efficacy and treatment durability—were the focus of a recent Ophthalmology Times Case-Based Roundtable®. The discussion also highlighted real-world experiences and evidence regarding extended treatment intervals…
What if? Ophthalmology without OCT – Part 3 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the company’s request for approval of its prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg.1 The FDA cited unresolved…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…
VR and imaging advancements showcased at AAO 2025 | Ophthalmology Times
Image credit: AdobeStock/Kittiphat The annual American Academy of Ophthalmology (AAO) meeting offered an opportunity for the ophthalmic industry to showcase their latest technologies designed to benefit patients and simplify the processes in an ophthalmology practice. Among the many products and…
Throwback Series: Managing childhood glaucoma in a resource-limited locale | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…